Literature DB >> 2510313

Cyclophosphamide use in a young woman with antiphospholipid antibodies and recurrent cerebrovascular accident.

M C Perez1, W A Wilson, E Scopelitis.   

Abstract

We have described a 25-year-old woman with recurrent cerebral thrombosis associated with very high levels of antibodies against phospholipids. Antinuclear antibodies and clinical features of a defined connective tissue disease were absent. Treatment with plasmapheresis, prednisone, intravenous cyclophosphamide, and warfarin was accompanied by disappearance from the serum of the lupus anticoagulant and the biologic false-positive test for syphilis; IgG anticardiolipin antibodies persisted, however, and the patient had a second cerebral thrombosis. Clinical improvement ultimately occurred after the dosage of cyclophosphamide was optimized and the level of IgG anticardiolipin antibody decreased to a level lower than any that has been previously associated with thrombotic complications.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510313     DOI: 10.1097/00007611-198911000-00021

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

Review 1.  Treatment of the antiphospholipid syndrome.

Authors:  J C Piette; M Karmochkine; T Papo; L T Du; C Francès; B Wechsler
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 2.  Primary antiphospholipid antibody syndrome and cerebral ischemia: report on acute intervention in two cases and literature review with emphasis on therapeutic options.

Authors:  S Braune; R Siekmann; P Vaith; C H Lücking
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

3.  Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.

Authors:  Amrie C Grammer; Rebecca Slota; Randy Fischer; Hanan Gur; Hermann Girschick; Cheryl Yarboro; Gabor G Illei; Peter E Lipsky
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 4.  B cell abnormalities in systemic lupus erythematosus.

Authors:  Amrie C Grammer; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2003-12-02       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.